Capricor Therapeutics, Inc. (CAPR) Stock

Capricor Therapeutics, Inc. (CAPR) is a Healthcare stock trading at $28.39 (as of 2026-06-18), with a market capitalization of $1.74B and a trailing P/E of -11.1. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

Capricor Therapeutics, Inc. develops cell- and exosome-based therapeutics, including CAP-1002, an allogeneic cardiac-derived cell therapy for late-stage Duchenne muscular dystrophy and for a Phase II study related to cytokine storm associated with SARS-CoV-2. The company also has CAP-2003 in pre-clinical development and additional vaccine candidates in development for potential COVID-19 prevention.

Valuation — source: SEC EDGAR (first-party)
Price	$28.39
Market Cap	$1.74B
P/E Ratio	-11.1
EV / EBITDA	-11.8
Price / Book	5.36
DCF Value (model)	$-16.52
DCF Upside vs Price	-158.2%

Profitability & Growth — source: SEC EDGAR
Revenue (TTM)	$0.00
Return on Equity	-41.1%
Current Ratio	8.42
Revenue Growth (YoY)	-100.0%
EPS Growth (YoY)	96.5%
FCF Growth (YoY)	76.7%

Financial Health — source: SEC EDGAR
Altman Z-Score	18.30 (safe)

Valuation vs Sector & Industry
Stock P/E	-11.1
Sector P/E (Healthcare)	21.0
Industry P/E (Pharmaceutical Products)	17.3
vs Sector	-153.1%
vs Industry	-164.4%

Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional Holder	SUVRETTA CAPITAL MANAGEMENT, LLC ($116.09M)
Institutional Holders Tracked	10

Company
Sector	Healthcare
Industry	Pharmaceutical Products
CEO	Linda Marbán
Employees	160
Country	US
IPO Date	2007-02-13

Related Companies (Business model: Biotech (Clinical / Commercial-Stage); 8 closest by market cap; US-domiciled)

Data as of 2026-06-18.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.